Investors

2023

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements.

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.